Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
RAHWAY, N.J.--(BUSINESS WIRE) October 10, 2022 -- Merck (NYSE: MRK), known as MSD... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 10, 2022 Category: Pharmaceuticals Source Type: clinical trials
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Monthly oral islatravir development for pre-exposure prophylaxis... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 20, 2022 Category: Pharmaceuticals Source Type: clinical trials
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Condition: Systemic Lupus Erythematosus Interventions: Drug: M5049 low dose; Drug: M5049 medium dose; Drug: M5049 high dose; Drug: Placebo Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating Padcev With Keytruda and Padcev as Monotherapy in First-Line Advanced Urothelial Cancer
TOKYO and BOTHELL, Wash. and RAHWAY, N.J., Sept. 12, 2022. Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ), Seagen Inc. ( Nasdaq:SGEN) and Merck ( NYSE: MRK), known as MSD outside of the United States and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 12, 2022 Category: Pharmaceuticals Source Type: clinical trials
PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants
Condition: Healthy Intervention: Drug: Xevinapant (Debio 1143) Sponsors: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2022 Category: Research Source Type: clinical trials
